Search Results 471-480 of 17049 for treatment resistant depression

  1. Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma - Mayo Clinic

    Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom ...

  2. Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma. Print details. Share; Facebook · Twitter.

  3. CAR-T Cell Therapy Program - Department home - Mayo Clinic

    CAR-T cell therapy may be a treatment option for: Relapsed, refractory B-cell acute lymphoblastic leukemia; Relapsed, refractory B-cell non-Hodgkin's lymphoma ...

  4. Oncology (Medical) - Clinical trials

    ... therapy of TILT-123 and pembrolizumab in patients with platinum resistant or refractory ovarian cancer. A Study of Tucatinib With Trastuzumab and mFOLFOX6 ...

  5. Rem-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS - Mayo Clinic

    The purpose of this study is to evaluate the safety and tolerability of REM-422 in patients with relapsed/refractory acute myeloid leukemia or higher-risk ...

  6. Treating Patients with Heart Failure Using a Respiratory Resistance Therapeutic Device - Mayo Clinic

    The purpose of this study is to investigate the potential benefits to pulmonary function using a unique respiratory “training mask” during exercise on patients ...

  7. Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough - Mayo Clinic

    Clinical Trials · Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough · More about research at Mayo ...

  8. Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior Chronic Myeloid Leukemia Therapies - Mayo Clinic

    Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior Chronic Myeloid Leukemia Therapies.

  9. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

    Clinical Trials · Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer · More about research at Mayo Clinic · Mayo ...

  10. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer - Mayo Clinic

    Clinical Trials · Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · More about research at Mayo ...